![]() |
|
|
Vol. 29, Issue 9, 1183-1189, September 2001
Departments of Psychology (C.E.L.) and Chemistry (L.S.), Rutgers,
The State University of New Jersey, Piscataway, New Jersey
To accurately assess the mechanism of involvement of the
active metabolite norcocaine in the effects of oral cocaine, it is essential to determine the rate and extent of the formation of norcocaine. Although this study was designed specifically for this aim,
it was also of interest to characterize the metabolite kinetics of
benzoylecgonine for comparative purpose. We first characterized the
pharmacokinetics of cocaine, norcocaine, and benzoylecgonine by the
i.v. route of administration; all three drugs decayed biexponentially.
These pharmacokinetic estimates were then used for determination of the
formation of norcocaine and benzoylecgonine after i.v. and p.o. (20-40
mg/kg) cocaine administration. Although
t1/2
, and
t1/2
were similar across the three
compounds, the values of volume of distribution in the central
compartment and clearance for benzoylecgonine were much smaller
than those of cocaine and norcocaine. Norcocaine was not detected
following i.v. cocaine; however, serum norcocaine concentrations were
as high as those of oral cocaine. Both routes of cocaine administration
produced benzoylecgonine. A pharmacokinetic model for the metabolite
kinetics was proposed by sequentially adding the models that most
adequately described the formation of each metabolite to the model of
cocaine. For oral cocaine, the absolute bioavailability was 3.48%,
whereas 6.04 and 2.26% of cocaine were converted to benzoylecgonine
and norcocaine, respectively, during first-pass absorption regardless
of dose. Furthermore, the majority of norcocaine and 92% of
benzoylecgonine were formed during the first-pass absorption, leaving
8% of benzoylecgonine produced in systemic circulation. The profile of
norcocaine as a metabolite confirmed the involvement of norcocaine in
cocaine's behavioral effects.
This article has been cited by other articles:
![]() |
H. Sun, M. L. Shen, Y.-P. Pang, O. Lockridge, and S. Brimijoin Cocaine Metabolism Accelerated by a Re-Engineered Human Butyrylcholinesterase J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 710 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Lau and L. Sun The Pharmacokinetic Determinants of the Frequency and Pattern of Intravenous Cocaine Self-administration in Rats by Pharmacokinetic Modeling Drug Metab. Dispos., March 1, 2002; 30(3): 254 - 261. [Abstract] [Full Text] [PDF] |
||||